Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
La reforma de salud en Bolivia: generando evidencia y sostenibilidad con gestión por resultados
Schwab N.; Pancorvo J.Caso P-1026Servicios y operacionesEn 1999, Bolivia dio comienzo a una reforma del sector salud basada en la evidencia. El caso describe los esfuerzos que hizo el Ministerio de Salud y Previsión Social para generar e institucionalizar una cultura gerencial basada en los resultados de establecer compromisos de gestión con las autoridades departamentales, con los objetivos e indicadores pertinentes. Los objetivos conciernen el plan de Seguro Básico de Salud (SBS) y el Programa Ampli...Desde 8,20 €
-
Celgene
Baker, Malcolm P.; McComb, Emily R.Caso HBS-218094-EFinanzasIn February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm's position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene's key drug, Revlimid. In response, Celgene's share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial i...Desde 8,20 €
-
Health Reform in Bolivia: Generating evidence and sustainability with performance-based management
Schwab N.; Pancorvo J.Caso P-1026-EServicios y operacionesIn 1999, Bolivia started an evidence based health reform. The case describes the efforts, the Ministry of Health and Social Provision undertook to generate and institutionalize a management culture based in results by establishing management contracts with the departmental authorities, with objectives and related indicators. The objectives concern the Basic Health insurance (SBS), the extended immunization program (PAI). The case describes the re...Desde 8,20 €
-
Celgene (B)
Baker, Malcolm P.; McComb, Emily R.Caso HBS-218099-EFinanzasIn February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm's position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene's key drug, Revlimid. In response, Celgene's share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial i...Desde 5,74 €